In the multivariate analysis, incident NPEP use remained significantly associated with younger age (hazard ratio 0.74, 95% CI 0.63–0.87, P trend < 0.001), previous NPEP use at study enrolment (hazard ratio 2.37, 95% CI 1.60–3.53, P < 0.001), higher levels of education (hazard ratio 1.18, 95% CI 1.04–1.34, P trend = 0.01) and reported UAI with casual partners by HIV status (hazard ratio 1.92, 95% CI 1.72–2.14, P trend < 0.001).
During follow-up, NPEP use increased significantly from 2.9 per 100 person-years in 2002 to 7.1 per 100 person-years in 2007 (P = 0.007) (Fig. 1). During the study, there was a significant increase in the number of men reporting NPEP use who reported no UAI exposures in the past 6 months (P = 0.04). However, it should be noted that apart from a peak of 3.75 per 100 person-years incident use in 2006, use in this low-risk group remained less than 2.0 per 100 person-years during the study period.
Behaviour change after nonoccupational postexposure prophylaxis use
Behavioural data before and 6 months after NPEP use were available for 154 incident reports of NPEP use. For the remaining 42, NPEP use was reported at the exit interview, and thus, no post-NPEP behavioural data were available. There was no significant increase or decrease in nonconcordant UAI overall, or in any category of UAI, by sexual position or by partner's HIV status, after NPEP use (Table 3). For 89 incident reports of NPEP use, behavioural data were available for at least 18 months after the NPEP use period. There was no significant change in HIV risk behaviour after NPEP use in this time period (data not shown).
Nonoccupational postexposure prophylaxis use and subsequent HIV seroconversion
By the end of the HIM study, there were 53 HIV seroconversions identified, giving an overall HIV incidence of 0.78 per 100 person-years (95% CI 0.59–1.02). The median age at HIV seroconversion was 37 years (range 22–63). Men who had previously received NPEP had an almost three-fold higher rate of HIV seroconversion subsequently (hazard ratio 2.67, 95% CI 1.40–5.08, P = 0.003). However, this was no longer significant after adjusting for sexual risk behaviour (hazard ratio 1.70, 95% CI 0.87–3.34, P = 0.123).
In this community-based cohort of homosexual men in Australia, awareness of the availability of NPEP was nearly universal. NPEP use increased rapidly from 2 to 7% of men each year over the life of the study. NPEP was used mostly by men who reported high-risk behaviours but was not associated with reductions in risk behaviour. Consequently, use was a significant predictor of future HIV infection. Thus, although NPEP use is likely to have averted HIV infections associated with specific exposures, NPEP did not reduce long-term risk of HIV infection in these high-risk individuals.
Knowledge of NPEP among HIM participants was very high (78.5% at baseline and 97.4% of participants by the final study year) compared with other studies. In a survey of 1819 HIV-uninfected gay/bisexual men in California conducted in 2006, 47% reported PEP awareness , and among male attendees of Minority Gay Pride Events in seven US cities in 2005 and 2006, only 21% had heard of people taking antiretrovirals to prevent HIV infection . The higher awareness of NPEP among Sydney gay men is probably related to targeted publicity campaigns and wide promotion of NPEP since 1999.
Younger men, men with a tertiary education and men who reported NPEP use at study enrolment were more likely to use NPEP during the study. Uptake of NPEP was very high in men reporting the highest risk behaviours, and the majority of reported NPEP use seemed clinically appropriate. Over 80% of use was during a period in which UAI was reported, and the incidence of NPEP use was less than 2% in men who reported no UAI in the past 6 months. In contrast, it was 20% or more for those who reported the highest risk anal sex behaviours. No one reported NPEP use more than three times, and only one in five of those who used NPEP used it more than once.
If NPEP is to have a significant population-level effect on HIV incidence, then it must be used after a substantial proportion of risk episodes. In the HIM study, over the 5-year study period involving 1427 participants, there were 1782 6-month periods in which nonconcordant UAI was reported. NPEP was used during 116 (6.5%) of these risk periods. This represents a small proportion of eligible exposures during the study period. A similar finding was seen in an intervention study on homosexual men in Brazil where NPEP starter packs were provided at baseline. In that study, only 57% of men who reported a high-risk exposure used NPEP, even though they had ready access to it . Thus, even though NPEP use increased significantly during the study period, and almost all HIM participants were aware of its availability, there was little evidence of overuse of NPEP in this population. After many risk episodes, participants may have underestimated their HIV risk  or accepted their level of HIV risk and did not seek NPEP . This raises the important question, which cannot be answered by this research, of why participants used NPEP for that particular occasion of risk but not for subsequent reported risk episodes.
The impact of NPEP on HIV risk behaviour has been investigated in observational studies in other countries. These have shown that NPEP use does not result in increased risk behaviour, particularly when combined with behavioural counselling [16,23]. The Brazilian study referred to above reported a decline in high-risk sexual activities among both NPEP users and nonusers who had access to NPEP starter packs . Among 397 people prescribed NPEP between 1997 and 1999 in San Francisco, there was a marked decrease in high-risk acts with high-risk partners in the 6–12 months after NPEP use. However, in that study, subsequent HIV risk behaviour was compared with risk behaviour in the 3 months prior to NPEP prescription, which included the risk episode leading to NPEP, and hence, the reduction in risk may simply represent regression to the mean . The largest dispenser of NPEP in Sydney is a hospital that is adjacent to the HIM study interview location and provides NPEP with routine adjunctive risk reduction counselling . Thus, it is likely that many NPEP recipients in HIM received behavioural counselling. Given this, the fact that we found no change in sexual behaviour 6 months after 154 incident NPEP uses and after at least 18 months for 89 incident NPEP uses is somewhat disappointing.
Prior NPEP users were around three times more likely to seroconvert to HIV, but this was explained by a higher prevalence of nonconcordant UAI among NPEP users. The higher risk of subsequent HIV seroconversion among men who reported NPEP use is unlikely to indicate NPEP failure but rather seroconversion related to risk episodes after NPEP completion.
This study had the strength of being a large-scale prospective cohort study. The sample was primarily community based, and we believe that it can be considered as broadly representative of gay HIV-negative men in Sydney. Participant identifiers were matched with the national HIV register to capture HIV seroconversions that may not have been detected in the HIM study. This method prevented any substantial underestimation of HIV incidence in this cohort due to loss to follow-up .
There were several important limitations in this study, including reliance on participants' self-report to measure NPEP use, which was not validated using clinical records. NPEP use was categorized into two time periods, 1 week to 6 months and 7 months to 1 year prior to interview. Potentially, this time range may have diluted the evidence of an immediate decrease in HIV risk behaviour. However, even if this was accurate, there is no evidence of a sustained effect of NPEP use on participants' HIV risk behaviour. In addition, this relatively wide time interval and the fact that we did not have data on adherence to NPEP meant we were not able to conclude with certainty whether any of the HIV infections after NPEP use were related to NPEP failure. Nevertheless, these results are consistent with the absence of HIV seroconversions in recent Australian NPEP studies [15,25].
This study clearly paints a picture of increasing and mainly appropriate use of NPEP among homosexual men in Sydney, Australia. The highest incidence of NPEP use was reported after the highest risk behaviours. However, there was no evidence of a long-term effect of NPEP on decreasing either HIV risk behaviour or HIV incidence. These data suggest that the current design of NPEP programmes needs to be reconsidered and indicate that if NPEP is to result in a decrease in personal HIV risk, then long-term targeted prevention interventions will be required in individuals who receive NPEP.
The authors thank all participants, the dedicated HIM study team and the participating doctors and clinics.
The National Centre in HIV Epidemiology and Clinical Research and the National Centre in HIV Social Research are funded by the Australian Government Department of Health and Ageing. The Health in Men cohort study was funded by the National Institutes of Health, a component of the US Department of Health and Human Services (NIH/NIAID/DAIDS: HVDDT Award N01-AI-05395), the National Health and Medical Research Council in Australia (project grant #400944), the Australian Government Department of Health and Ageing (Canberra) and the New South Wales Health Department (Sydney). I. Mary Poynten is funded by a National Health and Medical Research Council Public Health Postgraduate scholarship.
All authors (I. Mary Poynten, Fengyi Jin, Limin Mao, Garrett P. Prestage, Susan C. Kippax, John M. Kaldor, John Imrie and Andrew E. Grulich) contributed to the design of the study and the development and critical revision of the manuscript. I. Mary Poynten formulated and performed the statistical analysis and interpreted the data. Fengyi Jin and Limin Mao were involved in the analysis and interpretation of the data. Andrew E. Grulich took overall responsibility for the project and provided epidemiological expertise. I. Mary Poynten drafted the manuscript, to which all authors contributed. All authors have seen and approved the final version of the manuscript.
There are no conflicts of interest.
1. Fisher M, Benn P, Evans B, Pozniak A, Jones M, MacLean S, et al
. UK guidelines for the use of postexposure prophylaxis
following sexual exposures. Int J STD AIDS 2006; 17:81–92.
2. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, et al
. Antiretroviral postexposure prophylaxis
after sexual, injection drug use or other nonoccupational
exposure to HIV
in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54(RR-2):1–20.
3. Almeda J, Casabona J, Simon B, Gerard M, Rey D, Puro V, Thomas T. Proposed recommendations for the management of HIV postexposure prophylaxis
after sexual, injecting drug or other exposures in Europe. Euro Surveill 2004; 9:35–40.
4. Correll P, Smith D, Grulich A. Post exposure prophylaxis for nonoccupational
exposure to HIV
. Experience in New South Wales one year after the guidelines. N S W Public Health Bull 2000; 11:114–117.
5. NPEP Reference Group. National guidelines for postexposure prophylaxis after nonoccupational exposure to HIV
. Sex Health
6. Australian National Council on AIDS HCRDA. Guidelines for the management and post exposure prophylaxis of individuals who sustain nonoccupational exposure to HIV
. ANCAHRD Bull
7. Tsai C, Follis K, Sabo A, Beck T, Grant R, Bischofberger N, et al
. Efficacy of postexposure prophylaxis
after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). Science 1995; 270:1197–1199.
8. Otten R, Smith D, Adams D, Pullium J, Jackson E, Kim C, et al
. Efficacy of postexposure prophylaxis
after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74:9771–9775.
9. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet
10. Roland M. Postexposure prophylaxis
after sexual exposure to HIV
. Curr Opin Infect Dis 2007; 20:39–46.
11. Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al
. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV
-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795–802.
12. Cardo D, Culver D, Ciesielski C, Srivastava P, Marcus R, Abiteboul D, et al
. A case-control study of HIV
seroconversion in healthcare workers after percutaneous exposure. N Engl J Med 1997; 337:1485–1490.
13. Shoptaw S, Rotheram-Fuller E, Landovitz R, Wang J, Moe A, Kanouse D, Reback C. Nonoccupational
post exposure prophylaxis as a biobehavioral HIV
-prevention intervention. AIDS Care 2008; 20:376–381.
14. Cohen M, Gay C, Kashuba A, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV
-1. Ann Intern Med 2007; 146:591–601.
15. Poynten I, Smith D, Cooper D, Kaldor J, Grulich A. The public health impact of widespread availability of nonoccupational postexposure prophylaxis
Med 2007; 8:374–381.
16. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH, Praca Onze Study Team. Behavioral impact, acceptability, and HIV incidence
among homosexual men with access to postexposure chemoprophylaxis for HIV
. J Acquir Immune Defic Syndr 2004; 35:519–525.
17. Jin F, Prestage G, Mao L, Kippax S, Pell C, Donovan B, et al
. Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV
-negative gay men: the Health in Men study. J Infect Dis 2006; 194:561–570.
18. Jin F, Prestage G, McDonald A, Ramacciotti T, Imrie J, Kippax S, et al
. Trend in HIV incidence
in a cohort of homosexual men in Sydney: data from the Health in Men study. Sex Health 2008; 5:109–112.
19. Rogers W. Regression standard errors in clustered samples. Stata Tech Bull 1993; 13:19–23.
20. Liu A, Kittredge P, Vittinghoff E, Raymond H, Ahrens K, Matheson T, et al
. Limited knowledge and use of HIV
post and preexposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008; 47:241–247.
21. Voetsch A, Heffelfinger J, Begley E, Jafa-Bhushan K, Sullivan P. Knowledge and use of preexposure and postexposure prophylaxis
among attendees of Minority Gay Pride events, 2005 through 2006. J Acquir Immune Defic Syndr 2006; 46:378–380.
22. Roland M. A model for community delivery of postexposure prophylaxis
after potential sexual exposure to HIV
. Sex Transm Dis 2007; 34:294–296.
23. Martin J, Roland M, Neilands T, Krone M, Bamberger J, Kohn R, et al
. Use of postexposure prophylaxis
infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18:787–792.
24. Guinot D, Ho M, Poynten I, McAllister J, Pierce A, Pell C, Grulich A. Cost-effectiveness of HIV nonoccupational postexposure prophylaxis
in Australia. HIV
Med 2009; 10:199–208.
25. Winston A, McAllister J, Amin J, Cooper D, Carr A. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV postexposure prophylaxis
Med 2005; 6:191–197.
Keywords:© 2009 Lippincott Williams & Wilkins, Inc.
biomedical prevention; HIV; HIV incidence; HIV prevention; nonoccupational; postexposure prophylaxis; risk behaviour